(CercleFinance.com) – The stock ended the session up nearly 1.3%. Stifel reaffirms its ‘buy’ recommendation on Arkema while lowering its target price from 139 to 123 euros, deciding to apply peer multiples in its valuation calculation method instead of the chemical group’s historical multiples.
“The second quarter should prove to be vigorous again and beat expectations”, nevertheless estimates the broker, which raises its EBITDA expectation for 2022 to 2.2 billion euros, but leaves its results forecast for 2023 practically unchanged.